Table 3.
Survival Analyses Results According to Clinicopathologic and Metabolic Parameters in EGFR-Mutated Patients
| No. of Patients (%) | Progression-Free Survival (PFS) | Overall Survival (OS) | |||||
|---|---|---|---|---|---|---|---|
| Median PFS (Months) | Univariate Analysis p | Multivariate Analysis Adjusted HR (95% CI) | Median OS (Months) | Univariate Analysis p | Multivariate Analysis Adjusted HR (95% CI) | ||
| All | 62 (100) | 15.3 | 28.5 | ||||
| Gender | 0.145 | 0.091 | |||||
| Female | 32 (52) | 17.4 | Reference | 34.3 | Reference | ||
| Male | 30 (47) | 14.1 | 1.57 (0.98–3.14) | 21.0 | 1.69 (0.74–2.85) | ||
| Age, yrs | 0.179 | 0.252 | |||||
| <65 | 28 (45) | 17.9 | Reference | 32.4 | Reference | ||
| ≥65 | 34 (55) | 14.2 | 1.14 (0.57–2.26) | 26.3 | 1.28 (0.73–1.93) | ||
| Smoking | 0.049 | 0.409 | NA | ||||
| Never | 38 (61) | 17.3 | Reference | 30.2 | |||
| Ever | 24 (39) | 12.2 | 2.08 (1.02–4.26) | 26.1 | |||
| ECOG performance status | 0.320 | NA | 0.078 | ||||
| 0, 1 | 51 (82) | 16.7 | 29.9 | Reference | |||
| ≥2 | 11 (18) | 13.4 | 26.2 | 1.08 (0.22–2.74) | |||
| Stage | 0.236 | 0.548 | NA | ||||
| IIIB | 5 (8) | 15.6 | Reference | 28.3 | |||
| IV | 57 (92) | 13.2 | 1.23 (0.56–2.73) | 24.5 | |||
| Metastatic organs | 0.088 | 0.011 | |||||
| 0–2 | 48 (79) | 17.3 | Reference | 31.3 | Reference | ||
| ≥3 | 14 (21) | 11.8 | 1.98 (0.35–3.14) | 17.0 | 2.11 (1.04–3.61) | ||
| Brain metastasis | 0.199 | 0.273 | |||||
| No | 48 (79) | 16.3 | Reference | 29.5 | Reference | ||
| Yes | 14 (21) | 14.4 | 1.20 (0.35–2.63) | 27.6 | 1.37 (0.65–3.41) | ||
| Liver metastasis | 0.362 | NA | 0.674 | NA | |||
| No | 55 (88) | 16.9 | 28.6 | ||||
| Yes | 7 (12) | 14.4 | 29.5 | ||||
| EGFR subtypes* | 0.459 | NA | 0.449 | NA | |||
| 19del | 35 (57) | 15.3 | 30.3 | ||||
| L858R | 25 (47) | 16.9 | 23.3 | ||||
| First-line treatment | 0.063 | 0.316 | NA | ||||
| Gefitinib/erlotinib | 22 (35) | 12.2 | 1.82 (0.92–3.56) | 24.3 | |||
| Afatinib | 40 (65) | 15.8 | Reference | 29.3 | |||
| SUVmax | 0.057 | 0.070 | |||||
| Low (<3.54) | 12 (20) | 16.1 | Reference | 32.3 | Reference | ||
| High (≥3.54) | 50 (80) | 12.4 | 1.15 (0.92–3.46) | 25.9 | 1.61 (0.89–3.17) | ||
| MTV1.5 | 0.015 | ||||||
| Low (<14.08) | 26 (42) | 20.8 | 0.010 | Reference | 36.1 | Reference | |
| High (≥14.08) | 36 (58) | 13.1 | 3.12 (1.35–6.67) | 24.3 | 4.18 (1.28–10.85) | ||
| TLG1.5 | 0.018 | ||||||
| Low (<69.86) | 31 (50) | 20.2 | 0.008 | Reference | 34.9 | Reference | |
| High (≥69.86) | 31 (50) | 13.0 | 3.26 (1.45–7.32) | 23.7 | 4.62 (1.26–12.11) | ||
| MTV2.5 | 0.023 | 0.036 | |||||
| Low (<4.28) | 25 (47) | 19.8 | Reference | 35.5 | Reference | ||
| High (≥4.28) | 37 (53) | 13.6 | 2.16 (1.05–4.44) | 24.6 | 2.04 (1.08–6.25) | ||
| TLG2.5 | 0.026 | 0.041 | |||||
| Low (<12.64) | 22 (35) | 20.1 | Reference | 35.6 | Reference | ||
| High (≥12.64) | 40 (65) | 13.9 | 2.19 (1.10–4.68) | 26.5 | 1.87 (1.02–6.33) | ||
Note: *Two patients harboring rare mutation were excluded.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; SUV, standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis; HR, hazard ratio; CI, confidence interval; NA, not applicable.